NEUROLEPTIC MALIGNANT SYNDROME: NEED FOR EARLY DIAGNOSIS AND THERAPY
Abstract
Background: Neuroleptic Malignant Syndrome (NMS) is a medical entity that has received littleattention in the clinical settings in Pakistan. The aim of our study was to review the predisposingfactors, outcomes and characteristics of in-patients diagnosed with NMS. Methods: Weperformed a retrospective chart review of all cases (age > 15 years) at a tertiary care center inKarachi between January 01, 1990 and November 30, 2001, diagnosed using ICD 10 coding. Datawas collected using a standardized data entry form and statistical analysis was performed usingEpi Info 6, Version 6.02. Results: There were a total of 20 patients diagnosed with NMS (11 maleand 9 female) in our study with a mean age of 46.6±15.9 years. Haloperidol was the mostfrequently responsible neuroleptic. Of the 18 patients on a neuroleptic, most developed NMS after8 weeks of therapy. There were 5 mortalities all of which were associated with septic shock.Fourteen patients recovered completely from the episode and did not have any neurologicsequelae. Conclusions: NMS is an important preventable clinical entity. Early diagnosis andjudicious use of antipsychotics is warranted to prevent mortality and heightened morbidity.Key Words: Neuroleptic malignant syndrome, antipsychotics, predisposing factorsReferences
Haddad PM. Neuroleptic Malignant Syndrome maybe caused
by other drugs. BMJ 1994; 308:200
Pearlman C, Wheadon D, Epstein S: Creatine kinase
elevation after neuroleptic treatment. Am J Psychiatry 1988;
:1018-1019
Toru M, Matsuda O, Makiguchi K, Sugano K. Neuroleptic
Malignant Syndrome-like state following withdrawal of antiParkinsonian drugs. J Nerv Ment Dis 1981; 169:324-327
Meltzer HY, Cola PA, Parsa M: Marked elevations of serum
creatine kinase activity associated with antipsychotics drug
treatment. Neuropsychpharmacology 1996; 15:395-405
Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome
in Parkinson’s disease after withdrawal or alteration of
dopaminergic therapy. Arch Intern Med 1991; 151:794-6
Scelsa SN, Simpson DM, McQuiston HL, Fineman A, Ault
K, Reichler B: Clozapine-induced myotoxicity in patients
with chronic psychotic disorders. Neurology 1996; 47:1518-
Friedman JH, Feinberg SS, Feldman RG. A Neuroleptic
malignant-like syndrome due to levodopa therapy
withdrawal. JAMA 1985; 254:2792-95
Ahmed SH, Haq I. Seven cases of neuroleptic malignant
syndrome. JPMA 1989 Aug; 39(8):216 20. Saeki H, Muneta S, Kobayashi T. Malignant Syndrome
associated with disseminated intravascular coagulation and a
high level of amylase in serum, followed by diabetic coma in
an elderly patient with Parkinson’s disease during L-Dopa
therapy. Nippon Ronen Igakkai Zasshi 1998 Feb; 35(2):139-
Pope HG, Keck JP, Mcelroy SL. Frequency and presentation
of neuroleptic malignant syndrome in a large psychiatric
hospital. Am J Psychiatry 1986; 143:1227-33
Rankin J. Cerebral vascular accidents in patients over the age
of 60:II. prognosis. Scot Med J 1957; 2:200
Takubo H, Harada T, Hashimoto T, Inaba Y, Kanazawa I,
Kuno S et al. A collaborative study on the malignant
syndrome in Parkinson’s disease and related disorders.
Parkinsonism Relat Disord. 2003 Apr; 9 Suppl 1:S31-41
Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement
disorders associated with atypical antipsychotics drugs. J
Clin Psychiatry. 2002;63 Suppl 4:12-9
Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med
Clin North Am 1993; 71:185-202 22. Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan
KA
, Antelo RE. Progression of symptoms in neuroleptic
malignant syndrome. J Nerv Ment Dis 1994 Mar;182(3):168-
Shalev A, Munitz H. The neuroleptic malignant syndrome:
agent and host interaction. Acta Psychiatr Scand 1986;
:337-47
Addonizio G, Susman VL, Roth SD: Neuroleptic Malignant
Syndrome: Review and analysis of 115 cases. Biol Psychiatry
; 22:1004-1020
Henderson VW, Wooten GF. Neuroleptic malignant
syndrome: a pathophysiologic role for the dopamine receptor
blockade? Neurology 1981; 1331:132-7
Deng MZ, Chen GQ, Phillips MR. Neuroleptic Malignant
Syndrome in 12 of 9,792 Chinese Inpatients Exposed to
Neuroleptics: A Prospective Study. Am J Psychiatry Sep
; 147(9):1149-1155
Keck PE, Pope HG, Cohen BM, McElory SL, Nierenberg
AA. Risk factors for neuroleptic malignant syndrome. Arch
Gen Psychiatry 1989; 46:914-8
Rosebush PI, Stewart TA. Prospective analysis of 24
episodes of neuroleptic malignant syndrome. Am J
Psychiatry 1989; 146:717-25
Addonizio G, Susman VL, Roth SD. Symptoms of
Neuroleptic Malignant Syndrome in 82 consecutive
Buckley PF, Hutchinson M. Neuroleptic Malignant inpatients. Am J Psychiatry 1986; 143:1587-1590
Syndrome. Neurol Neurosurg Psychiatry 1995; 58:271-273 26. Price WA, Giannini AJ. A paradoxical response to
chlorpromazine – a possible variant of the neuroleptic
malignant syndrome. J Clin Pharmacol 1983; 23:567-569
O’Dwyer A, Sheppard P. The role of creatine kinase in the
diagnosis of neuroleptic malignant syndrome. Psychol Med
; 23:323-6 27. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study
of neuroleptic malignant syndrome. Am J Psychiatry Aug
; 154:1156-1158.
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
